REVIEW ARTICLE
Concentrated insulins: History and critical reappraisal
浓缩胰岛素:历史以及关键的再评价
Lutz Heinemann,
John M. Beals,
James Malone,
James Anderson,
Jennie G. Jacobson,
Vikram Sinha, Sheila M. Corrigan,
Lutz Heinemann
Science Consulting in Diabetes, Düsseldorf, Germany
Search for more papers by this authorCorresponding Author
John M. Beals
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Correspondence
John M. Beals, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Tel: +1 317 276 1682
Fax: +1 317 277 2934
Email: [email protected]
Search for more papers by this authorJames Malone
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorJames Anderson
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorJennie G. Jacobson
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorSheila M. Corrigan
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorLutz Heinemann,
John M. Beals,
James Malone,
James Anderson,
Jennie G. Jacobson,
Vikram Sinha, Sheila M. Corrigan,
Lutz Heinemann
Science Consulting in Diabetes, Düsseldorf, Germany
Search for more papers by this authorCorresponding Author
John M. Beals
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Correspondence
John M. Beals, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
Tel: +1 317 276 1682
Fax: +1 317 277 2934
Email: [email protected]
Search for more papers by this authorJames Malone
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorJames Anderson
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorJennie G. Jacobson
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorSheila M. Corrigan
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
Search for more papers by this authorAbstract
enThe earliest marketed insulins were crude acidic formulations with concentrations of ≤10 units/mL. Since the early 1920s, insulins have improved continually, via bioengineering, process, and chemical modifications. Today, most insulin formulations have a concentration of 100 units/mL (U100). However, more concentrated insulin formulations (200, 300, and 500 units/mL; U200, U300, and U500, respectively) are also available. There is a tendency to assume that concentrated insulins are similar, both to each other and to their U100 counterparts, but this is not always the case: two concentrated insulins, namely insulin degludec U200 and insulin lispro U200, are bioequivalent to their U100 counterparts, whereas regular human insulin U500 and insulin glargine U300 are not. The advent of these concentrated insulins offers greater opportunities to provide tailored therapy for patients; it also introduces potential confusion, and highlights the need for prescriber and patient education. Precise and accurate dedicated insulin delivery devices are also necessary for the safe use of these concentrated insulins. Although some clinicians only use concentrated insulin with obese and severely insulin-resistant patients, other patients would also benefit from the reduced injection volume associated with concentrated insulins, or the modified time-action profile of some concentrated insulins. The aim of this review is to enhance understanding of the historic development and the safe and effective use of concentrated insulins in clinical practice.
Abstract
zh摘要
最早上市的胰岛素是浓度≤ 10单位/mL的酸性粗制剂。自从20世纪20年代初以来, 通过生物工程、加工以及化学修饰不断地对胰岛素进行改良。如今, 大多数胰岛素制剂的浓度都是100单位/mL(U100)。然而, 如今还有更浓的胰岛素制剂(分别为200、300与500单位/mL;U200、U300与U500)。有一种倾向性的意见认为浓缩胰岛素都相类似, 既彼此相似, 也与对应的U100剂型相似, 但是却并非总是如此:有两种浓缩胰岛素, 即德谷胰岛素U200与赖脯胰岛素U200,它们生物等效于各自对应的U100剂型, 而常规人胰岛素U500与甘精胰岛素U300却不是这样。这些浓缩胰岛素的出现为患者提供了更多的特定治疗;但是它们也潜在地带来了困惑, 并且突显了处方医生与患者教育的需求。为了安全地使用这些浓缩胰岛素, 还需要有精准的专用胰岛素注射装置。虽然一些临床医生只对肥胖与严重胰岛素抵抗的患者使用浓缩胰岛素, 但是其他患者也将受益于与浓缩胰岛素相关的注射量减少, 或者受益于一些浓缩胰岛素的时间—作用曲线的改善。本综述的目的是加强我们对浓缩胰岛素历史研制过程的了解, 并且促进我们在临床实践中安全有效地使用浓缩胰岛素。
REFERENCES
- 1Korsatko S, Deller S, Koehler G et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013; 33: 515–521.
- 2de la Pena A, Seger M, Soon D et al. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog(R)) 100 U/mL. Clin Pharmacol Drug Dev. 2016; 5: 69–75.
- 3Lane WS, Cochran EK, Jackson JA et al. High-dose insulin therapy: Is it time for U-500 insulin? Endocr Pract. 2009; 15: 71–79.
- 4 Sanofi. A study to demonstrate bioequivalence between insulin glulisine U300 and insulin glulisine U100 after a single subcutaneous dose using the euglycemic clamp technique, in patients with type 1 diabetes mellitus. Clinicaltrials.gov; 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02910518 (accessed 3 October 2017).
- 5Bliss M. Who discovered insulin. In: The Discovery of Insulin. McClelland and Stewart, Toronto, Canada, 1982; 189–211.
10.1007/978-1-349-09612-1_9 Google Scholar
- 6Scheller JC, Galloway JA. The development of the insulin unit. Am J Pharm Sci Support Public Health. 1975; 147: 29–32.
- 7Sahyun M, Blatherwick N. The rabbit method of standardizing insulin. Am J Physiol. 1926; 76: 677–684.
- 8 Houghton Mifflin Trade. The American Heritage Stedman's Medical Dictionary; 2002. International Insulin Unit.
- 9Hagedorn HC, Jensen BN, Krakup NB et al. Protamine insulinate. JAMA. 1936; 106: 177–180.
- 10Schlichtkrull J, Munck O, Jersild M. Insulin rapitard and insulin actrapid. Acta Med Scand. 1965; 177: 103–113.
- 11Nicol DS, Smith LF. Amino-acid sequence of human insulin. Nature. 1960; 187: 483–485.
- 12Bell GI, Pictet RL, Rutter WJ, Cordell B, Tischer E, Goodman HM. Sequence of the human insulin gene. Nature. 1980; 284: 26–32.
- 13Owens DR. Human Insulin: Clinical Pharmacological Studies in Normal Man. MTP Press, Hingham, MA, 1986.
10.1007/978-94-009-4161-8 Google Scholar
- 14Bloom A, Keen H, Watkins PJ. A change to 100-unit insulin dosage will reduce errors. Br Med J (Clin Res Ed). 1981; 283: 33–34.
- 15Moss JM, Galloway JA. U-100 insulin. A progress report. JAMA. 1977; 238: 1823–1824.
- 16Watkins JD, Roberts DE, Williams TF, Martin DA, Coyle V. Observation of medication errors made by diabetic patients in the home. Diabetes. 1967; 16: 882–885.
- 17Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia. 1994; 37: 377–380.
- 18Heinemann L, Chantelau EA, Starke AA. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin. Diabet Metab. 1992; 18: 21–24.
- 19 European Medicines Agency. Tresiba, insulin degludec. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002498/human_med_001609.jsp&mid=WC0b01ac058001d124 (accessed 4 April 2017).
- 20 European Medicines Agency. NovoRapid, insulin aspart. 2016. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000258/human_med_000935.jsp&mid=WC0b01ac058001d124 (accessed 4 April 2017).
- 21 European Medicines Agency. Humalog, insulin lispro. 2017. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000088/human_med_000820.jsp&mid=WC0b01ac058001d124 (accessed 4 April 2017).
- 22 European Medicines Agency. Apridra, insulin glulisine. 2017. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000557/human_med_000648.jsp&mid=WC0b01ac058001d124 (accessed 4 April 2017).
- 23 European Medicines Agency. Lantus, insulin glargine. 2017. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000284/human_med_000882.jsp&mid=WC0b01ac058001d124 (accessed 4 April 2017).
- 24 European Medicines Agency. Levemir, insulin detemir. 2017. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000528/human_med_000884.jsp&mid=WC0b01ac058001d124 (accessed 4 April 2017).
- 25Kaiserman K, Jung H, Benabbad I, Karges B, Polak M, Rosilio M. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence. Pediatr Diabetes. 2017; 18: 81–94.
- 26 Eli Lilly & Company. Humalog 100 units/mL, solution for injection in vial, cartridge, pre-filled pen (KwikPen), and Junior KwikPen. 2014. Available from: https://www.medicines.org.uk/EMC/medicine/9314/SPC/Humalog+100U+ml,+solution+for+injection+in+vial,++Humalog+100U+ml,++solution+for+injection+in+Cartridge,++Humalog+Pen+100U+ml,+solution+for+injection/ (accessed 4 December 2015).
- 27Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units·mL−1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units·mL−1. Diabetes Care. 2015; 38: 637–643.
- 28de la Pena A, Riddle M, Morrow LA et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011; 34: 2496–2501.
- 29de la Pena A, Ma S, Reddy S, Ovalle F, Bergenstal RM, Jackson JA. Application of PK/PD modeling and simuliation to dosing regimen optimization of high-dose human regular U-500 insulin. J Diabetes Sci Technol. 2014; 8: 821–829.
- 30Nosek L, Roggen K, Heinemann L et al. Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Diabetes Obes Metab. 2013; 15: 77–83.
- 31Lauritzen T, Pramming S, Gale EA, Deckert T, Binder C. Absorption of isophane (NPH) insulin and its clinical implications. Br Med J (Clin Res Ed). 1982; 285: 159–162.
- 32Becker RH, Frick AD, Nosek L, Heinemann L, Rave K. Dose–response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care. 2007; 30: 2506–2507.
- 33Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001; 40: 641–659.
- 34Gagnon-Auger M, du Souich P, Baillargeon JP et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010; 33: 2502–2507.
- 35Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose–response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005; 28: 1107–1112.
- 36Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007; 9: 290–299.
- 37Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017; 19: 3–12.
- 38Owens DR. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opin Drug Metab Toxicol. 2016; 12: 977–987.
- 39Soeborg T, Rasmussen CH, Mosekilde E, Colding-Jorgensen M. Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci. 2009; 36: 78–90.
- 40Hood RC, Arakaki RF, Wysham C, Li YG, Settles JA, Jackson JA. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycymic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to-target clinical trial. Endocr Pract. 2015; 21: 782–793.
- 41 European Medicines Agency, Committee for Medicinal Products for Human Use Guideline on the Investigation of Bioequivalence. European Medicines Agency, London, 2010.
- 42 U.S. Food and Drug Administration, U.S. Department of Health and Human Services. Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs - general considerations. 2014. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm389370.pdf (accessed 3 October 2017).
- 43Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015; 17: 386–394.
- 44Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 1 diabetes: a randomized, Phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015; 38: 2217–2225.
- 45Matsuhisa M, Koyama M, Cheng X et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Obes Metab. 2016; 18: 375–383.
- 46Riddle MC, Bolli GB, Home PD et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/mL in people with type 2 diabetes. Diabetes Technol Ther. 2016; 18: 252–257.
- 47Riddle MC, Bolli GB, Ziemen M et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014; 37: 2755–2762.
- 48Riddle MC, Yki-Jarvinen H, Bolli GB et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015; 17: 835–842.
- 49Terauchi Y, Koyama M, Cheng X et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab. 2016; 18: 366–374.
- 50Bode BW, Chaykin LB, Sussman AM et al. Efficacy and safety of insulin degludec 200 U/mL and insulin degludec 100 U/mL in patients with type 2 diabetes (Begin: Compare). Endocr Pract. 2014; 20: 785–791.
- 51Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. Diabetes Care. 2013; 36: 2536–2542.
- 52 Sanofi-Adventis. Toujeo prescribing information. 2015. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf (accessed 10 October 2018).
- 53Cochran EK, Valentine V, Samaan KH, Corey IB, Jackson JA. Practice tips and tools for the successful use of U-500 regular human insulin: the diabetes educator is key. Diabetes Educ. 2014; 40: 153–165.
- 54 International Diabetes Federation (IDF) Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2013. Diabetes Res Clin Pract. 2015; 109: 461–465.
- 55Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364–1379.
- 56Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008; 32: 1431–1437.
- 57Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384: 766–781.
- 58Simonson GD, Kendall DM. Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. Coron Artery Dis. 2005; 16: 465–472.
- 59Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: 782–787.
- 60Rees TM, Curtis BH, Gaskins KA et al. Efficacy and safety of insulin lispro in obese patients with type 2 diabetes: a retrospective metaanalysis of 7 randomized controlled trials. Endocr Pract. 2014; 20: 389–398.
- 61Watson L, Wilson BP, Alsop J, Kumar S. Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation? Diabetes Obes Metab. 2011; 13: 823–831.
- 62Segal AR, El Sayed N. Are you ready for more insulin concentrations? J Diabetes Sci Technol. 2015; 9: 331–338.
- 63Eby EL, Van Brunt K, Brusko C, Curtis B, Lage MJ. Insulin dosing and outcomes among commercially insured patients with type 2 diabetes in the United States. Clin Ther. 2015; 37: 2297–2308 e1.
- 64Eby EL, Wang P, Curtis BH et al. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ. 2013; 16: 529–538.
- 65Heise T, Nosek L, Dellweg S et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014; 16: 971–976.
- 66Idris I, Peng X, He X et al. The trend of high-dose insulin usage among patients with diabetes in the UK: a retrospective study. Diabetes Ther. 2018. https://doi.org/10.1007/s13300-018-0515-0 [Epub ahead of print.].
- 67Bulchandani DG, Konrady T, Hamburg MS. Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007; 13: 721–725.
- 68Hatipoglu B, Soni S, Espinosa V. Glycemic control with continuous subcutaneous insulin infusion with use of U-500 insulin in a pregnant patient. Endocr Pract. 2006; 12: 542–544.
- 69Knee TS, Seidensticker DF, Walton JL, Solberg LM. Lasseter DH. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003; 9: 181–186.
- 70Lane WS, Weinrib S, Pendleton E, Lane B. U200 lispro improves glucose control compared to U500 regular insulin in continuous subcutaneous insulin infusion (CSII) in patients with diabetes with high insulin requirements. Endocr Pract. 2016; 22: 329–330.
- 71 U.S. National Library of Medicine. U-500R insulin in type 2 diabetes with severe insulin resistance via Omnipod. 2017. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00606034?term=pump&cond=insulin+500&rank=1 (accessed 1 November 2017).
Citing Literature
